Exploring the mechanism of Jia Wei Xing Bi Gel nasal drops on Children with Allergic Rhinitis based on Transcriptomics and Network Pharmacology

Methods

A total of 56 AR children were randomly divided into Jia Wei Xing Bi Gel nasal drops(JWXBGND) group and mometasone furoate nasal spray (MFGS) group, with 28 cases in each group, and a healthy control group of 20 cases. After 4 weeks of treatment, efficacy was evaluated, and RNA-seq, database mining, and bioinformatics analysis methods were employed. Results: In terms of clinical efficacy, the TCM group showed better improvement in nasal itching, ocular symptoms, non-nasal ocular symptoms, and behavioral issues compared to the western medicine group, with a more significant decrease in TCM syndrome scores; transcriptomic analysis revealed 2776 differentially expressed genes when comparing AR children with healthy children, and 441 differential genes were identified between JWXBGND group and MFGS group; combined analysis of transcriptomics and network pharmacology identified 195 active components and 493 targets of action for Jiawei Xingbi Gel, with core components including ferulic acid, fexofenadine, and curcumin A, and core targets involving TNF, IL-6, IL-1β, AKT1, ALB, SRC, etc.; KEGG pathway analysis mainly enriched in caffeine metabolism, linoleic acid metabolism, Th17 cell differentiation, HIF-1 signaling pathway, etc.; molecular docking results indicated that key active components of Jia Wei Xing Bi Gel nasal drops bind stably to targets such as ALB, AKT1, SRC, TP53, etc.